REG - Ilika plc - Senior appointment&conversion of preference shares

IlikaAnnouncement

16/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230616:nRSP9129Ca&default-theme=true

RNS Number : 9129C  Ilika plc  16 June 2023

 

Ilika plc

("Ilika" or the "Company")

 

Appointment of Vice President Product Development

 Conversion of preference shares, total voting rights and award of share
options update

 

Ilika (AIM: IKA), a pioneer in solid-state battery technology, today provides
an update on senior appointments, a notice of conversion of preference shares,
total voting rights, and an update to staff share option awards.

 

VP Product Development

With effect from 1 September 2023, Ilika has appointed Dr. Louise Turner to
the role of VP Product Development. Promoted from her current position as
Technical Director, Louise has demonstrated her skills in overseeing both the
scientific development and scale-up activities of the Stereax® product and
can draw on both her Doctorate in Chemistry and MBA in Business &
Technology to further the Ilika story.

 

Louise will take over line management responsibility for Ilika's Stereax and
Goliath product development programmes from Robin Bell. Robin will continue to
work with and support the Company in an advisory capacity as New Product
Introduction Director where he will continue supporting each product in its
journey to market.

 

Ilika's CEO Graeme Purdy, stated: "We are delighted to have the opportunity
to promote such a capable leader and scientist as Louise to the senior
management team. Louise will build on the product development and
commercialisation work that she has delivered with the Stereax team to the
wider business helping to enact the same scale up and delivery in the Goliath
product roadmaps. We look forward to continuing our relationship with Robin in
his new technical consulting role."

 

Conversion of preference shares

Ilika announces that following receipt of conversion notices in relation to
426,300 convertible preferred Ordinary Shares of one penny each, it has today
issued 426,300 Ordinary Shares. Accordingly, the Company has applied to the
London Stock Exchange for 426,300 Ordinary Shares to be admitted to trading on
AIM ("Admission"). It is expected that Admission will occur at 8:00 a.m. on 19
June 2023.

 

Total Voting Rights

Following Admission, the Company's issued share capital will comprise
158,900,667 Ordinary Shares and that number may be used by shareholders in the
Company as the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change in their
interest in, the share capital of the Company under the FCA's Disclosure
Guidance and Transparency Rules. The Company does not hold any shares in
treasury.

 

Award of share options update

The Company also announces that as part of the Company's EMI option scheme, in
addition to the 802,248 options granted over ordinary shares of one penny each
in the Company ("Ordinary Shares") on 1 March 2023, the Company awarded an
additional 350,138 market value options to employees on 1 March 2023.
Therefore, an aggregate of 1,572,140 options over Ordinary Shares had been
granted to employees under the EMI option scheme on 1 March 2023, representing
0.99% of issued share capital.

 

For more information contact:

 Ilika plc                                               www.ilika.com (http://www.ilika.com/)
 Graeme Purdy, Chief Executive                           Via Walbrook PR

 Liberum Capital Limited (Nomad and Joint Broker)        Tel: 020 3100 2000
 Andrew Godber,
 William Hall, Nikhil Varghese

 Joh. Berenberg, Gossler & Co. KG (Joint Broker)         Tel: 020 3207 8700
 Matthew Armitt, Mark Whitmore, Detlir Elezi,
 Mara Grasso

 Walbrook PR Ltd             Tel: 020 7933 8780 / Ilika@walbrookpr.com
 Lianne Applegarth                                       Mob: 07584 391 303
 Nick Rome                                               Mob: 07748 325 236
 Tom Cooper                                              Mob: 07971 221 972

 

About Ilika plc

Ilika specialises in the development of solid-state batteries. Its Stereax®
product line is designed for miniature medical devices and specialist internet
of Things (IoT) applications. Stereax® enables disruptive product designers
looking for an intrinsically safe, long life (1000s recharges), low leakage
(nA) and miniature power source in a rectangular form factor similar to ICs.
For more information about Ilika, please visit:  https://www.ilika.com
(https://www.ilika.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAKKSFSSDEFA